Table 1

Demographic data, diagnosis and ongoing therapies at the time of enrolment

Whole
cohort (101)
CTDs
(54)
IA
(32)
SV
(15)
P value
Female, N (%)78 (77)
Age at enrolment (mean±SD)57.4±14.355.6±14.163.2±10.251.1±18.70.02
Disease duration (mean±SD)12.8±10.412.7±10.616.5±11.56±5.30.04
Hypogammaglobulinaemia, N (%)10 (9.9)4 (7.4)5 (14.2)1 (6.6)ns
Ongoing therapies
 GCs36 (35.5%)22 (40.7%)6 (18.7%)8 (53.3%)0.03
 Daily dose prednisone equivalent (mean±SD)4.6±44.8±4.43.5±0.85±4.5ns
 Antimalarials42 (41.5%)37 (68.5%)5 (15.6%)0<0.01
 cDMARDs47 (46.5%)24 (44%)19 (59.3)4 (26.6)ns
  Methotrexate24 (23.7%)5 (9.2%)16 (50%)3 (20%)<0.01
  Azatioprine5 (4.9%)4 (7.4%)01 (6.6%)ns
  Mycophenolate mofetil9 (8.9%)9 (16.6%)000.01
  Cyclosporine4 (3.9%)4 (7.4%)00ns
  Cyclophosphamide2 (1.9%)2 (3.7%)00ns
  Tacrolimus1 (0.9%)1 (1.8%)00ns
  Leflunomide2 (1.9%)02 (6.25%)0ns
 cDMARDs+GC14 (13.8%)9 (16.6%)4 (12.5%)1 (6.6%)ns
 bDMARDs35 (34.6%)2 (3.7%)23 (42.6%)10 (66.6%)<0.01
  TNF-alpha inhibitors20 (19.8%)014 (43.7%)6 (40%)<0.01
  Tocilizumab3 (2.9%)01 (3.1%)2 (13.3%)0.02
  Abatacept8 (7.9%)08 (25%)0<0.01
  Belimumab2 (1.9%)2 (3.7%)00ns
  Mepolizumab2 (1.9%)002 (13.3%)0.03
 IVIg7 (6.9%)6 (11.1%)1 (3.1%)0ns
 Rituximab within the last 2 years*4 (3.9%)2 (3.7%)1(3.1%)1(6.6%)ns
 No treatment, N (%)3 (2.9)
  • *Patients received last dose of rituximab at least 5 months before vaccination.

  • bDMARDs, biological disease-modifying antirheumatic drugs; cDMARDs, conventional disease-modifying antirheumatic drugs; CTDs, connective tissue diseases; GCs, glucocorticoids; IA, inflammatory arthritis; IVIg, intravenous immunoglobulin; ns, not significant; SV, systemic vasculitis.